All In Biotech

Investigational drug · Phase 3

Iptilimumab

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Brain Tumor, Non Small Cell Lung Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "Iptilimumab"

First trial start

2022

Aug 12, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Iptilimumab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Brain Tumor
  • Non Small Cell Lung Cancer

Approved drugs for the same conditions: Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Iptilimumab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Brain Tumor

  • APL-101Phase 21 trial

    Apollomics Inc. · Solid Tumors, Advanced Cancer, Renal Cancer

  • BCB-276Phase 21 trial

    BrainChild Bio, Inc · Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor

  • RVP-001Mn-PyC3A, mangaveratePhase 21 trial

    Reveal Pharmaceuticals Inc. · Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms

  • TNG456Phase 21 trial

    Tango Therapeutics, Inc. · Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.